Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines

Overview

Journal Can J Gastroenterol

Specialty Gastroenterology

Date 2012 Dec 19

PMID 23248795

Citations 35

Authors

Carla S Coffin

Scott K Fung

Mang M Ma

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B (CHB) is a dynamic disease that is influenced by host and virological factors. The management of CHB has become more complex with the increasing use of long-term oral nucleos⁄tide analogue antiviral therapies and the availability of novel diagnostic assays. Furthermore, there is often a lack of robust data to guide optimal management such as the selection of therapy, duration of treatment, potential antiviral side effects and the treatment of special populations. In November 2011, the Canadian Liver Foundation and the Canadian Association for the Study of the Liver convened a consensus conference to review the literature and analyze published data, including other international expert guidelines on CHB management. The proceedings of the consensus conference are summarized and provide updated clinical practice guidelines to assist Canadian health care providers in the prevention, diagnosis, assessment and treatment of CHB.

Citing Articles

Virological Response to Lamivudine and Tenofovir Treatment in a Mono-infected Chronic Hepatitis B Patient with Potential Tenofovir Resistance: A Case Report.

Dahiya M, Tai T, Hussaini T, Ritchie G, Matic N, Yoshida E J Clin Transl Hepatol. 2025; 13(1):84-87.

PMID: 39801782 PMC: 11712090. DOI: 10.14218/JCTH.2024.00248.

Prevalence of Hepatitis B in Canadian First-Time Blood Donors: Association with Social Determinants of Health.

OBrien S, Ehsani-Moghaddam B, Goldman M, Drews S Viruses. 2024; 16(1).

PMID: 38257817 PMC: 11326446. DOI: 10.3390/v16010117.

IL2-inducible T-cell Kinase is Required for HBV-induced Type T Interferon Expression and Antiviral Response.

Lin M, Guo R, Zeng D, Liu J, Zheng M, Su Z J Clin Transl Hepatol. 2023; 11(4):918-924.

PMID: 37408826 PMC: 10318274. DOI: 10.14218/JCTH.2022.00299.

Hepatocellular carcinoma screening practices among patients with chronic hepatitis B by Canadian gastroenterologists and hepatologists: An online survey.

Lun Yau A, Galorport C, Coffin C, Ko H Can Liver J. 2022; 2(4):199-209.

PMID: 35992766 PMC: 9202808. DOI: 10.3138/canlivj.2019-0012.

Importance of fibrosis stage in starting treatment for hepatitis B virus (HBV): Are the updated CASL/AMMI HBV clinical algorithms lost in translation?.

Burak K, Sadler M, Borman M, Congly S Can Liver J. 2022; 2(4):131-134.

PMID: 35992760 PMC: 9202814. DOI: 10.3138/canlivj.2019-0019.

References

van Zonneveld M, van Nunen A, Niesters H, de Man R, Schalm S, Janssen H . Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003; 10(4):294-7. DOI: 10.1046/j.1365-2893.2003.00440.x. View

Moses S, Lim Z, Zuckerman M . Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011; 9(10):891-9. DOI: 10.1586/eri.11.105. View

Chang M, Hsu H, Hsu H, Ni Y, Chen J, Chen D . The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995; 22(5):1387-92. View

Sanchez-Tapias J, Costa J, Mas A, Bruguera M, Rodes J . Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology. 2002; 123(6):1848-56. DOI: 10.1053/gast.2002.37041. View

Roche B, Samuel D . The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011; 31 Suppl 1:104-10. DOI: 10.1111/j.1478-3231.2010.02396.x. View

Beasley R . Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61(10):1942-56. DOI: 10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j. View

Piccinino F, Sagnelli E, Pasquale G, Giusti G . Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2(2):165-73. DOI: 10.1016/s0168-8278(86)80075-7. View

Geretti A, Doyle T . Immunization for HIV-positive individuals. Curr Opin Infect Dis. 2009; 23(1):32-8. DOI: 10.1097/QCO.0b013e328334fec4. View

Mohamed A, Al Karawi M, Mesa G . Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology. 1997; 44(17):1404-6. View

10.

Liu C, Chuang W, Lee C, Yu M, Lu S, Wu S . Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2008; 136(2):496-504.e3. DOI: 10.1053/j.gastro.2008.10.049. View

11.

Peters M, Hann Hw H, Martin P, Heathcote E, Buggisch P, Rubin R . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2003; 126(1):91-101. DOI: 10.1053/j.gastro.2003.10.051. View

12.

Raimondo G, Brunetto M, Pontisso P, Smedile A, Maina A, Saitta C . Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2005; 43(1):100-7. DOI: 10.1002/hep.20944. View

13.

Shapiro R, Steinbrecher U, Magil A . Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. Am J Nephrol. 1995; 15(4):343-7. DOI: 10.1159/000168861. View

14.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

15.

Wong D, Cheung A, ORourke K, Naylor C, Detsky A, Heathcote J . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119(4):312-23. DOI: 10.7326/0003-4819-119-4-199308150-00011. View

16.

Liu C, Kao J, Chen D . Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005; 25(6):1097-107. DOI: 10.1111/j.1478-3231.2005.01177.x. View

17.

Colonno R, Rose R, Baldick C, Levine S, Pokornowski K, Yu C . Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology. 2006; 44(6):1656-65. DOI: 10.1002/hep.21422. View

18.

Low E, Cox A, Atkins M, Nelson M . Telbivudine has activity against HIV-1. AIDS. 2009; 23(4):546-7. DOI: 10.1097/QAD.0b013e3283262f09. View

19.

. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011; 60(50):1709-11. View

20.

Jang J, Choi J, Bae S, Yoon S, Chang U, Kim C . A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43(2):233-40. DOI: 10.1002/hep.21024. View